

2654-785.1

Protein Binding and Drug Transport

Symposium Alvor, Algarve, Portugal
24th–28th September, 1985

Editors:

Jean-Paul Tillement
Elke Lindenlaub

With 134 figures
and 85 tables



F. K. SCHATTAUER VERLAG · STUTTGART – NEW YORK

Contents

Prof. Jacques-Robert BOISSIER	1
Opening Address · K. HELLWICH	3
Introduction · J.-P. TILLEMENT	5

The Different Types of Drug Binding in Blood

Chairman: D. J. BIRKETT

Albumin as a Specific Binding Protein for Drugs and Endogenous Compounds · D. J. BIRKETT, S. WANWIMOLRUK	11
Discussion: BIRKETT, CHIGNELL, MÜLLER, PERRIN, URIEN, UZAN	25
Drug Binding to Human α_1 -Acid Glycoprotein. Focus on a Single Binding Site · W. E. MÜLLER, S. RICK, F. MÜLLER	29
Discussion: BARRÉ, BIRKETT, BLASCHKE, FICHTL, LINDUP, MÜLLER, WALTER, WANWIMOLRUK	45
Drug Binding to Erythrocytes · M. EHRNEBO	49
Discussion: BARRÉ, BIRKETT, EHRNEBO, MEYER, TILLEMENT, WALTER, V. WASIELEWSKI, WEISIGER, ZAHLTEN	59
Interaction of Drugs with Human Plasma Lipoproteins · S. URIEN	63
Discussion: BIRKETT, EHRNEBO, ERICSSON, FICHTL, LEMAIRE, TESTA, URIEN, WALTER	77
Drug Binding to Leucocytes and Platelets · M. LEMAIRE	79
Discussion: BRIAND, HAJDÚ, LEMAIRE, SJÖQVIST, TILLEMENT, UZAN	91
Drug-Immunoglobulin Interactions · E. ALBENGRES	95
Protein Binding of Different Penbutolol Conjugates · P. HAJDÚ, K. H. LEHR	103
Discussion: ALBENGRES, BIRKETT, D'ARCY, FICHTL, HAJDÚ, MÜLLER, SJÖQVIST, TILLEMENT, V. WASIELEWSKI	109

The Different Types of Drug Binding in Blood

Chairman: C. CHIGNELL

Bonds Between Drugs and Plasma Components · J. H. PERRIN	115
Discussion: MÜLLER, PARDRIDGE, PERRIN, TESTA, UZAN, WEISIGER	129
Structure Binding Relationships for Sites I and II on Albumin · S. WANWIMOLRUK, D. J. BIRKETT	133
Discussion: BIRKETT, MÜLLER, PERRIN, WANWIMOLRUK	153
Cisplatin Plasma Protein Binding as an Example of Irreversible Binding · C. BRIAND, M. BOURDEAUX, R. MOMBURG	155
Discussion: BIRKETT, BOURDEAUX, BRIAND, CHIGNELL, LINDUP	169
Serum Binding of Ramipril and Its Metabolites in Vitro and in Vivo · H. G. ECKERT, M. VOLZ, H.-M. KELLNER	171

Discussion: ECKERT, PARDRIDGE	177
Respective Parts of the Different Plasma Proteins and Blood Cells in the Overall Binding of Drugs P. A. ROUTLEDGE	179
Discussion: BIRKETT, CHIGNELL, EHRNEBO, FICHTL, ROUTLEDGE	197
Plasma Protein Binding and Drug Interactions · P. F. D'ARCY, J. C. McELNAY	199
Discussion: BELPAIRE, BIRKETT, BLASCHKE, CHIGNELL, D'ARCY, PARDRIDGE, SJÖQVIST, UZAN, WALTER	207

Kinetic and Mechanistic Aspects of Drug Measurements Within the Body

Chairman: G. R. WILKINSON

Drug Binding and Apparent Volume of Distribution · G. HOUIN	213
Discussion: BARRÉ, BELPAIRE, HOUIN, ROUTLEDGE, TILLEMENT, WILKINSON	227
Binding of Drugs to Blood Components and Renal Elimination · L. P. BALANT	231
Discussion: BALANT, BARRÉ, LEVY, LINDUP, WILKINSON	247
Serum Protein Binding and Pharmacokinetics of Cephalosporins · M. LIMBERT, G. SEIBERT	249
Discussion: LEVY, LIMBERT, PARDRIDGE, WILKINSON	253
Relationships Between Plasma- and Tissue-Binding of Drugs · B. FICHTL, G. SCHUHMAN	255
Discussion: FICHTL, SJÖQVIST, UZAN, WALTER, WANWIMOLRUK, WEISIGER, WILKINSON	273
Transport of Plasma Protein-Bound Drugs into Tissues in Vivo · W. M. PARDRIDGE	277
Non-Equilibrium Drug Binding and Hepatic Drug Removal · R. A. WEISIGER	293
Plasma Binding and Brain Uptake of Benzodiazepines · D. R. JONES, S. D. HALL, R. A. BRANCH, E. K. JACKSON, G. R. WILKINSON	311
General Discussion: D'ARCY, EHRNEBO, LEVY, LINDUP, MÜLLER, PARDRIDGE, UZAN, WALTER, WANWIMOLRUK, WEISIGER, WILKINSON, WILLIAMS, ZAHLTEN	325

Drug Binding Modifications and Altered Kinetics in Pathological States

Chairman: H.-P. KUEMMERLE

Introductory Remarks · H.-P. KUEMMERLE	335
Qualitative Changes of Proteins as a Cause of Altered Drug Binding in Serum · S. ERILL, R. CALVO	337
Discussion: BIRKETT, ERILL, FICHTL, KUEMMERLE, LINDUP, MÜLLER, ROUTLEDGE, WANWIMOLRUK, WEISIGER	349
Modification of Drug Binding and Pharmacokinetics in Acute Myocardial Infarction T. F. BLASCHKE, H. Y.-M. PAN	353
Discussion: BLASCHKE, LEVY, PARDRIDGE, ROUTLEDGE, UZAN, WALTER	371
Protein Binding in Hepatic Disease: Pharmacokinetic and Clinical Implications · R. L. WILLIAMS	375
Discussion: KUEMMERLE, LEVY, SJÖQVIST, WALTER, WEISIGER, WILKINSON, WILLIAMS	393
Drug Binding Defect of Uraemic Plasma: Contribution of Endogenous Binding Inhibitors W. E. LINDUP, K. A. BISHOP, R. COLLIER	397
Discussion: CHIGNELL, ERILL, LEVY, LINDUP, MÜLLER, WALTER	415

New Trends in Drug Binding and Drug Transport

Chairman: B. TESTA

Chairman's Opening Remarks: Some Physicochemical Considerations Related to Drug Binding and Drug Transport · B. TESTA	421
Blood Binding and Drug Monitoring · F. SJÖQVIST	429
Discussion: D'ARCY, HAJDÚ, SJÖQVIST, WILLIAMS	443
Pharmacological Consequences of Warfarin-Protein Binding · G. LEVY, W. K. CHEUNG	445
Discussion: BIRKETT, CHIGNELL, FICHTL, LEVY, ROUTLEDGE, SJÖQVIST, WALTER, WILKINSON	455
Pharmacological Consequences of Binding of β -Adrenergic Blocking Agents to α_1 -Acid Glycoprotein · F. M. BELPAIRE, P. MUGABO, M. G. BOGAERT	459
Discussion: BELPAIRE, ERILL, UZAN	471
The Possible Pharmacological Significances of the Tissue Binding of an Antibiotic · J. BARRÉ, R. ZINI, M. P. FOURNET, M. BRANDEBOURGER, J.-P. TILLEMENT	473
Discussion: BARRÉ, D'ARCY, EHRNEBO, FROMSON, LEVY, PARDRIDGE, TILLEMENT, WALTER	483
Blood Cells and Drug Targeting · A. UZAN, C. GUÉRÉMY, G. LE FUR	487
Discussion: BLASCHKE, CHIGNELL, MÜLLER, UZAN, WALTER	503
Protein Binding – An Industrial Viewpoint · J. M. FROMSON	507
Discussion: BIRKETT, FROMSON, LEVY, SJÖQVIST, WANWIMOLRUK, WILKINSON	515
General Discussion: BLASCHKE, FICHTL, LEVY, LINDUP, ROUTLEDGE, WILLIAMS	519
Concluding Remarks: J.-P. TILLEMENT	523
Index	527